CCL2 and neoplasm: Because a previous study reported that the suspension of CCL2 neutralizing antibody therapy could lead to rapid tumor recurrence due to monocyte release from the bone marrow and blood vessel formation [15], we also discontinued Mogamulizumab therapy to investigate the recurrence of tumor in this study.